MedTrace Logo

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

NCT01125449 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-18

No results posted yet for this study

Summary

The study is designed to determine if high doses of intravenous ascorbic acid (vitamin C) can be effective in managing solid tumor diseases. Secondary goals are determination of any palliative effects and improvement of quality of life of patients.

Conditions

  • Sarcoma
  • Adenocarcinoma
  • Carcinoma
  • Multiple Myeloma
  • Desmoplastic Small Round Cell Tumor

Interventions

DRUG

Ascorbic acid (vitamin C)

Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.

Sponsors & Collaborators

  • Situs Cancer Research Center

    lead OTHER

Principal Investigators

  • G D Murphy, MD · Situs Cancer Research Center

  • J Bolt, PhD · Situs Cancer Research Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-06-30
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125449 on ClinicalTrials.gov